Revenue - Ryvu Therapeutics SA (WSE:RVU) - Alpha Spread
R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 54.2 PLN -0.18% Market Closed
Market Cap: 1.3B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Revenue Peer Comparison

Comparables:
I
IGN
M
MDB
S
SLV

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Revenue
zł55.6m
CAGR 3-Years
88%
CAGR 5-Years
3%
CAGR 10-Years
N/A
I
Inno-Gene SA
WSE:IGN
Revenue
zł462k
CAGR 3-Years
-68%
CAGR 5-Years
-28%
CAGR 10-Years
-19%
M
Medicofarma Biotech SA
WSE:MDB
Revenue
zł750.8k
CAGR 3-Years
-41%
CAGR 5-Years
-31%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Revenue
zł337.3m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Ryvu Therapeutics SA's Revenue?
Revenue
55.6m PLN

Based on the financial report for Mar 31, 2024, Ryvu Therapeutics SA's Revenue amounts to 55.6m PLN.

What is Ryvu Therapeutics SA's Revenue growth rate?
Revenue CAGR 5Y
3%

Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Ryvu Therapeutics SA have been 88% over the past three years , 3% over the past five years .

Back to Top